News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
Views & Analysis Will UK patients get access to novel drugs? Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F... Lilly's drug will be re-appraised in 2020
News Amgen’s myeloma treatment Kyprolis gains NICE approval NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
